Can glucose‐lowering medications improve outcomes in non‐diabetic heart failure patients? A Bayesian network meta‐analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Can glucose‐lowering medications improve outcomes in non‐diabetic heart failure patients? A Bayesian network meta‐analysis
Authors
Keywords
-
Journal
ESC Heart Failure
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-01-29
DOI
10.1002/ehf2.13822
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
- (2021) Chloe Wong et al. Frontiers in Endocrinology
- Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class
- (2021) Evie K. Bain et al. DIABETES OBESITY & METABOLISM
- Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years
- (2021) Riobaldo M Cintra et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
- (2021) Emily Brown et al. LANCET
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction — A Win against a Formidable Foe
- (2021) Mark H. Drazner NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
- (2020) Da-Peng Zhang et al. Cardiovascular Diabetology
- Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
- (2020) Fabio Marsico et al. EUROPEAN HEART JOURNAL
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
- (2020) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs
- (2019) Osamah M. Alfayez et al. Primary Care Diabetes
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
- (2019) John J.V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of sodium glucose cotransporter type 2 inhibitors on heart failure
- (2019) Michael E. Nassif et al. DIABETES OBESITY & METABOLISM
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
- (2019) Yue Fei et al. Cardiovascular Diabetology
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses
- (2019) Audrey Béliveau et al. BMC Medical Research Methodology
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- A randomised, double‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes
- (2019) Anders Hostrup Larsen et al. EUROPEAN JOURNAL OF HEART FAILURE
- GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
- (2018) Xiaoming Jia et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cardiovascular Effects of New Oral Glucose-Lowering Agents
- (2018) André J. Scheen CIRCULATION RESEARCH
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review
- (2018) Karin Rådholm et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Diabetes pharmacotherapy and effects on the musculoskeletal system
- (2018) Evangelia Kalaitzoglou et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Efficacy and safety of empagliflozin for type 2 diabetes mellitus
- (2018) Yun-Jing Zhang et al. MEDICINE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study
- (2017) Roni Nielsen et al. JOURNAL OF NUCLEAR CARDIOLOGY
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE
- (2016) Søren L. Kristensen et al. Circulation-Heart Failure
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiopulmonary Exercise Testing in Heart Failure
- (2016) Rajeev Malhotra et al. JACC-Heart Failure
- Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis
- (2015) Takeyuki Hiramatsu et al. THERAPEUTIC APHERESIS AND DIALYSIS
- The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis
- (2014) C J Taylor et al. BMJ Open
- Automating network meta-analysis
- (2012) Gert van Valkenhoef et al. Research Synthesis Methods
- Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
- (2010) Mads Halbirk et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More